<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230034</url>
  </required_header>
  <id_info>
    <org_study_id>UNIPV001DIM2010</org_study_id>
    <secondary_id>2010-023332-17</secondary_id>
    <nct_id>NCT01230034</nct_id>
  </id_info>
  <brief_title>Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria</brief_title>
  <official_title>Randomized, Controlled, PROBE Trial, Evaluating the Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic Patients and Mild to Moderate Hypertension With Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous clinical and experimental data show that the elective treatment of diabetic
      nephropathy should be based on drugs that inhibit the renin-angiotensin system (RAS).
      Albuminuria is a marker of risk not only renal but also cardiovascular and diabetic patients
      with concomitant non-diabetic nephropathy, on the other hand, drugs blocking the
      renin-angiotensin system available so far, namely ACE inhibitors and angiotensin antagonists
      II have proven effective in reducing proteinuria in power even if different therapeutic drug
      to drug. ACE inhibitors are one of the most known and used treatment options for blocking the
      renin-angiotensin system in patients with microalbuminuria. Drugs such as enalapril,
      lisinopril and ramipril are standard therapy in diabetic patients with micro or
      macroalbuminuria. However, it is still unclear whether their efficacy is, from this point of
      view, the same or varies from drug to drug. This is particularly true in the diabetic
      microalbuminuria, a condition in which there is sufficient documentation to prove that
      ramipril is effective. The main objective of this study was to assess the magnitude and trend
      of the time and to the antiproteinuric effect of antihypertensive 10-20mg/die imidapril
      versus ramipril 5-10 mg / day in hypertensive patients with type 2 diabetes and
      microalbuminuria.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of the reduction of urinary albumin in 24 hours to the various controls</measure>
    <time_frame>After 12 weeks from the beginning</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Size of the reduction of mean 24-hour average daytime and nighttime average. 2. Size of the reduction of central blood pressure. 3. Magnitude of changes in plasma concentrations of angiotensin II, bradykinin and BNP after 24 weeks of treatment.</measure>
    <time_frame>After 12 weeks from the beginning</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Microalbuminuria</condition>
  <arm_group>
    <arm_group_label>Imidapril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 and 20 mg/day, pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 and 10 mg/day, pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>pill, 5 and 10 mg/day, od, 24 weeks</description>
    <arm_group_label>Ramipril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imidapril</intervention_name>
    <description>pill, 10 and 20 mg/day, od, 24 weeks</description>
    <arm_group_label>Imidapril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blood pressure&gt; 130/80 â‰¤ 170/100 mmHg at the end of the period of wash-out

          -  Type 2 diabetes mellitus well controlled by medication and / or compliance with diet
             (HbA1c &lt;7%)

          -  Microalbuminuria in the upper range of normal (&gt; 150 &lt;300 mg/24 h)

        Exclusion Criteria:

          -  Pregnancy, lactation or women of childbearing age.

          -  Inability to stop treatment in place for a few days during the wash-out.

          -  Sitting diastolic blood pressure&gt; 100 mmHg or systolic pressure&gt; 170 at the end of the
             wash-out.

          -  History of hypertensive encephalopathy or cerebrovascular accident within 12 months
             prior.

          -  Secondary hypertension.

          -  Heart failure

          -  Acute myocardial infarction; angina pectoris

          -  Liver and kidney dysfunction

          -  Known hypersensitivity to ACE inhibitors

          -  All other physiological or pathological condition that the physician may affect the
             evaluation of the parameters under study or interfere with the proper conduct of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Fogari, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto Fogari, MD</last_name>
    <phone>+39 0382 526217</phone>
    <email>r.fogari@unipv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Derosa, MD</last_name>
    <phone>+39 0382 502614</phone>
    <email>giuseppe.derosa@unipv.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pavia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD</last_name>
      <phone>+39 0382 526217</phone>
      <email>giuseppe.derosa@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Derosa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2010</study_first_submitted>
  <study_first_submitted_qc>October 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2010</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. GianMario Frigo</name_title>
    <organization>University of Pavia</organization>
  </responsible_party>
  <keyword>Imidapril, Ramipril, Hypertension, Type 2 diabetes mellitus, Microalbuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Imidapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

